Regeneron has been busy, with two health tech deals announced this week: One is about genetic data and one about AI. Both of ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against Billionaire Mario Gabelli’s other large-cap stock picks with huge upside potential.

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective reduced by Truist Financial from $975.00 to $940.00 in a research note released on Wednesday,Benzinga reports.

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment ...

Regeneron Pharmaceuticals ... This agreement, along with our $3.6 billion expansion of our Tarrytown, New York, R&D and preclinical manufacturing facilities, our fill/finish facility in Rensselaer ...

Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to emerge as a profitable commercial operation and establish a narrow moat.

Regeneron’s bispecific antibody linvoseltamab has received conditional approval from the European Commission (EC) for use in relapsed or refractory multiple myeloma. The decision comes just eight ...

Regeneron shares were down nearly 9% in afternoon trading and have lost more than a fifth of their value so far this year. Tarrytown, N.Y.-based Regeneron also said that its plan to make its ...

Regeneron faced mixed results in Q1 2025 with challenges in its retinal franchise offset by strong pipeline progress and Dupixent’s robust performance. The company remains focused on resolving ...